{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T10:51:43Z","timestamp":1793962303404,"version":"4.8.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T00:00:00Z","timestamp":1622851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T00:00:00Z","timestamp":1622851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2020YFA0509400"],"award-info":[{"award-number":["2020YFA0509400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970196"],"award-info":[{"award-number":["81970196"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670200"],"award-info":[{"award-number":["81670200"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) is still incurable and characterized by clonal expansion of plasma cells in the bone marrow (BM). Therefore, effective therapeutic interventions must target both myeloma cells and the BM niche.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cell proliferation, drug resistance, and chromosomal instability (CIN) induced by CHEK1 were confirmed by Giemsa staining, exon sequencing, immunofluorescence and xenograft model in vivo. Bone lesion was evaluated by Tartrate-resistant acid phosphatase (TRAP) staining. The existence of circCHEK1_246aa was evaluated by qPCR, Sanger sequencing and Mass Spectrometer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We demonstrated that CHEK1 expression was significantly increased in human MM samples relative to normal plasma cells, and that in MM patients, high CHEK1 expression was associated with poor outcomes. Increased CHEK1 expression induced MM cellular proliferation and evoked drug-resistance in vitro and in vivo. CHEK1-mediated increases in cell proliferation and drug resistance were due in part to CHEK1-induced CIN. CHEK1 activated CIN, partly by phosphorylating CEP170. Interestingly, CHEK1 promoted osteoclast differentiation by upregulating NFATc1 expression. Intriguingly, we discovered that MM cells expressed circCHEK1_246aa, a circular CHEK1 RNA, which encoded and was translated to the CHEK1 kinase catalytic center. Transfection of circCHEK1_246aa increased MM CIN and osteoclast differentiation similarly to CHEK1 overexpression, suggesting that MM cells could secrete circCHEK1_246aa in the BM niche to increase the invasive potential of MM cells and promote osteoclast differentiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings suggest that targeting the enzymatic catalytic center encoded by CHEK1 mRNA and circCHEK1_246aa is a promising therapeutic modality to target both MM cells and BM niche.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-021-01380-0","type":"journal-article","created":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T02:04:54Z","timestamp":1622858694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma"],"prefix":"10.1186","volume":"20","author":[{"given":"Chunyan","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongfang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Jurczyszyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Janz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meral","family":"Beksac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghuang","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Seckinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxuan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0228-5102","authenticated-orcid":false,"given":"Ye","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,5]]},"reference":[{"issue":"6","key":"1380_CR1","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3322\/caac.21252","volume":"64","author":"G Bianchi","year":"2014","unstructured":"Bianchi G, Anderson KC. Understanding biology to tackle the disease: multiple myeloma from bench to bedside, and back. CA Cancer J Clin. 2014;64(6):422\u201344. https:\/\/doi.org\/10.3322\/caac.21252.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"1380_CR2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrc.2017.63","volume":"17","author":"C Pawlyn","year":"2017","unstructured":"Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer. 2017;17(9):543\u201356. https:\/\/doi.org\/10.1038\/nrc.2017.63.","journal-title":"Nat Rev Cancer"},{"key":"1380_CR3","doi-asserted-by":"publisher","unstructured":"Gu C, Lu T, Wang W, Shao M, Wei R, Guo M, et al. RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma. Leukemia. 2020. https:\/\/doi.org\/10.1038\/s41375-020-01033-z.","DOI":"10.1038\/s41375-020-01033-z"},{"issue":"1","key":"1380_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25(1):91\u2013101. https:\/\/doi.org\/10.1016\/j.ccr.2013.12.015.","journal-title":"Cancer Cell"},{"key":"1380_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3324\/haematol.2017.182121","volume":"1","author":"C Gu","year":"2018","unstructured":"Gu C, Cheng H, Yang H, Bian Y, Wang Y, Zhang Y, et al. MK2 is a therapeutic target for high-risk multiple myeloma. Haematologica. 2018;1:1. https:\/\/doi.org\/10.3324\/haematol.2017.182121.","journal-title":"Haematologica"},{"issue":"17","key":"1380_CR6","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1182\/blood-2009-05-220285","volume":"114","author":"Y Zheng","year":"2009","unstructured":"Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood. 2009;114(17):3625\u20138. https:\/\/doi.org\/10.1182\/blood-2009-05-220285.","journal-title":"Blood"},{"issue":"11","key":"1380_CR7","doi-asserted-by":"publisher","first-page":"djw131","DOI":"10.1093\/jnci\/djw131","volume":"108","author":"Y Zheng","year":"2016","unstructured":"Zheng Y, Wang Q, Li T, Qian J, Lu Y, Li Y, et al. Role of myeloma-derived MIF in myeloma cell adhesion to bone marrow and chemotherapy response. J Natl Cancer Inst. 2016;108(11):djw131. https:\/\/doi.org\/10.1093\/jnci\/djw131.","journal-title":"J Natl Cancer Inst"},{"key":"1380_CR8","volume-title":"Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease","author":"H Liu","year":"2019","unstructured":"Liu H, He J, Koh SP. Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease, vol. 11; 2019."},{"issue":"20","key":"1380_CR9","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","volume":"125","author":"G Bianchi","year":"2015","unstructured":"Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015;125(20):3049\u201358. https:\/\/doi.org\/10.1182\/blood-2014-11-568881.","journal-title":"Blood"},{"issue":"4","key":"1380_CR10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrclinonc.2017.197","volume":"15","author":"IM Ghobrial","year":"2018","unstructured":"Ghobrial IM, Detappe A, Anderson KC, Steensma DP. The bone-marrow niche in MDS and MGUS: implications for AML and MM. Nat Rev Clin Oncol. 2018;15(4):219\u201333. https:\/\/doi.org\/10.1038\/nrclinonc.2017.197.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"1380_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41408-018-0060-0","volume":"8","author":"C Gu","year":"2018","unstructured":"Gu C, Holman C, Sompallae R, Jing X, Tomasson M, Hose D, et al. Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome. Blood Cancer J. 2018;8(2):22. https:\/\/doi.org\/10.1038\/s41408-018-0060-0.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1380_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood-2009-03-210526","volume":"115","author":"L Chen","year":"2010","unstructured":"Chen L, Wang S, Zhou Y, Wu X, Entin I, Epstein J, et al. Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. Blood. 2010;115(1):61\u201370. https:\/\/doi.org\/10.1182\/blood-2009-03-210526.","journal-title":"Blood"},{"issue":"1","key":"1380_CR13","doi-asserted-by":"publisher","first-page":"8983","DOI":"10.1038\/ncomms9983","volume":"6","author":"MA Lawson","year":"2015","unstructured":"Lawson MA, McDonald MM, Kovacic N, Hua Khoo W, Terry RL, Down J, et al. Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat Commun. 2015;6(1):8983. https:\/\/doi.org\/10.1038\/ncomms9983.","journal-title":"Nat Commun"},{"issue":"6","key":"1380_CR14","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1200\/JCO.2014.57.9961","volume":"33","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol. 2015;33(6):657\u201364. https:\/\/doi.org\/10.1200\/JCO.2014.57.9961.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1380_CR15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cell.2015.05.053","volume":"162","author":"F Dietlein","year":"2015","unstructured":"Dietlein F, Kalb B, Jokic M, Noll EM, Strong A, Tharun L, et al. A synergistic interaction between Chk1- and MK2 inhibitors in KRAS-mutant Cancer. Cell. 2015;162(1):146\u201359. https:\/\/doi.org\/10.1016\/j.cell.2015.05.053.","journal-title":"Cell"},{"key":"1380_CR16","doi-asserted-by":"publisher","first-page":"722","DOI":"10.3389\/fonc.2019.00722","volume":"9","author":"M Guo","year":"2019","unstructured":"Guo M, Sun D, Fan Z, Yuan Y, Shao M, Hou J, et al. Targeting MK2 is a novel approach to interfere in multiple myeloma. Front Oncol. 2019;9:722. https:\/\/doi.org\/10.3389\/fonc.2019.00722.","journal-title":"Front Oncol"},{"issue":"3","key":"1380_CR17","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3324\/haematol.2018.208306","volume":"105","author":"H de Boussac","year":"2020","unstructured":"de Boussac H, Bruyer A, Jourdan M, Maes A, Robert N, Gourzones C, et al. Kinome expression profiling to target new therapeutic avenues in multiple myeloma. Haematologica. 2020;105(3):784\u201395. https:\/\/doi.org\/10.3324\/haematol.2018.208306.","journal-title":"Haematologica"},{"issue":"3","key":"1380_CR18","doi-asserted-by":"publisher","first-page":"e89064","DOI":"10.1371\/journal.pone.0089064","volume":"9","author":"XY Pei","year":"2014","unstructured":"Pei XY, Dai Y, Felthousen J, Chen S, Takabatake Y, Zhou L, et al. Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1\/2 inhibition in human multiple myeloma cells. PLoS One. 2014;9(3):e89064. https:\/\/doi.org\/10.1371\/journal.pone.0089064.","journal-title":"PLoS One"},{"issue":"8","key":"1380_CR19","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-11-0949","volume":"11","author":"HJ Landau","year":"2012","unstructured":"Landau HJ, McNeely SC, Nair JS, Comenzo RL, Asai T, Friedman H, et al. The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells. Mol Cancer Ther. 2012;11(8):1781\u20138. https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0949.","journal-title":"Mol Cancer Ther"},{"issue":"19","key":"1380_CR20","doi-asserted-by":"publisher","first-page":"5189","DOI":"10.1182\/blood-2011-02-339432","volume":"118","author":"XY Pei","year":"2011","unstructured":"Pei XY, Dai Y, Youssefian LE, Chen S, Bodie WW, Takabatake Y, et al. Cytokinetically quiescent (G0\/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1\/2. Blood. 2011;118(19):5189\u2013200. https:\/\/doi.org\/10.1182\/blood-2011-02-339432.","journal-title":"Blood"},{"issue":"1","key":"1380_CR21","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41392-020-00281-w","volume":"5","author":"D Sun","year":"2020","unstructured":"Sun D, Tao W, Zhang F, Shen W, Tan J, Li L, et al. Trifolirhizin induces autophagy-dependent apoptosis in colon cancer via AMPK\/mTOR signaling. Signal Transduct Target Ther. 2020;5(1):174. https:\/\/doi.org\/10.1038\/s41392-020-00281-w.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"1380_CR22","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108(6):2020\u20138. https:\/\/doi.org\/10.1182\/blood-2005-11-013458.","journal-title":"Blood"},{"issue":"14","key":"1380_CR23","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1182\/blood-2009-12-261032","volume":"116","author":"A Broyl","year":"2010","unstructured":"Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010;116(14):2543\u201353. https:\/\/doi.org\/10.1182\/blood-2009-12-261032.","journal-title":"Blood"},{"issue":"23","key":"1380_CR24","doi-asserted-by":"publisher","first-page":"11986","DOI":"10.18632\/oncotarget.2388","volume":"5","author":"Y Yang","year":"2014","unstructured":"Yang Y, Zhou W, Xia J, Gu Z, Wendlandt E, Zhan X, et al. NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma. Oncotarget. 2014;5(23):11986\u201397. https:\/\/doi.org\/10.18632\/oncotarget.2388.","journal-title":"Oncotarget"},{"issue":"8","key":"1380_CR25","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1182\/blood-2006-09-044974","volume":"109","author":"G Mulligan","year":"2007","unstructured":"Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007;109(8):3177\u201388. https:\/\/doi.org\/10.1182\/blood-2006-09-044974.","journal-title":"Blood"},{"issue":"1","key":"1380_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ccr.2012.12.001","volume":"23","author":"W Zhou","year":"2013","unstructured":"Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W, et al. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell. 2013;23(1):48\u201362. https:\/\/doi.org\/10.1016\/j.ccr.2012.12.001.","journal-title":"Cancer Cell"},{"issue":"44","key":"1380_CR27","doi-asserted-by":"publisher","first-page":"78234","DOI":"10.18632\/oncotarget.20829","volume":"8","author":"W Wang","year":"2017","unstructured":"Wang W, Zhang Y, Chen R, Tian Z, Zhai Y, Janz S, et al. Chromosomal instability and acquired drug resistance in multiple myeloma. Oncotarget. 2017;8(44):78234\u201344. https:\/\/doi.org\/10.18632\/oncotarget.20829.","journal-title":"Oncotarget"},{"key":"1380_CR28","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.ccell.2018.04.010","volume":"33","author":"B Canovas","year":"2018","unstructured":"Canovas B, Igea A, Sartori AA, Gomis RR, Paull TT, Isoda M, et al. Targeting p38alpha Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells. Cancer Cell. 2018;33:1094\u20131110.e1098.","journal-title":"Cancer Cell"},{"issue":"3","key":"1380_CR29","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2174\/1389202918666170705150819","volume":"19","author":"G Liu","year":"2018","unstructured":"Liu G, Ye CJ, Chowdhury SK, Abdallah BY, Horne SD, Nichols D, et al. Detecting chromosome condensation defects in gulf war illness patients. Curr Genomics. 2018;19(3):200\u20136. https:\/\/doi.org\/10.2174\/1389202918666170705150819.","journal-title":"Curr Genomics"},{"issue":"9","key":"1380_CR30","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1091\/mbc.e12-07-0528","volume":"24","author":"Y Hara","year":"2013","unstructured":"Hara Y, Kimura A. An allometric relationship between mitotic spindle width, spindle length, and ploidy in Caenorhabditis elegans embryos. Mol Biol Cell. 2013;24(9):1411\u20139. https:\/\/doi.org\/10.1091\/mbc.e12-07-0528.","journal-title":"Mol Biol Cell"},{"issue":"10","key":"1380_CR31","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1091\/mbc.E18-10-0674","volume":"30","author":"D Ganapathi Sankaran","year":"2019","unstructured":"Ganapathi Sankaran D, Stemm-Wolf AJ, Pearson CG. CEP135 isoform dysregulation promotes centrosome amplification in breast cancer cells. Mol Biol Cell. 2019;30(10):1230\u201344. https:\/\/doi.org\/10.1091\/mbc.E18-10-0674.","journal-title":"Mol Biol Cell"},{"key":"1380_CR32","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ccell.2017.09.002","volume":"32","author":"F Gulluni","year":"2017","unstructured":"Gulluni F, Martini M, De Santis MC, Campa CC, Ghigo A, Margaria JP, et al. Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2alpha Scaffolding Function. Cancer Cell. 2017;32:444\u2013459.e447.","journal-title":"Cancer Cell"},{"issue":"1","key":"1380_CR33","doi-asserted-by":"publisher","first-page":"15057","DOI":"10.1038\/ncomms15057","volume":"8","author":"N Huang","year":"2017","unstructured":"Huang N, Xia Y, Zhang D, Wang S, Bao Y, He R, et al. Hierarchical assembly of centriole subdistal appendages via centrosome binding proteins CCDC120 and CCDC68. Nat Commun. 2017;8(1):15057. https:\/\/doi.org\/10.1038\/ncomms15057.","journal-title":"Nat Commun"},{"issue":"3","key":"1380_CR34","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/jnci\/djx166","volume":"110","author":"Y Yang","year":"2018","unstructured":"Yang Y, Gao X, Zhang M, Yan S, Sun C, Xiao F, et al. Novel role of FBXW7 circular RNA in repressing glioma tumorigenesis. J Natl Cancer Inst. 2018;110(3):304\u201315. https:\/\/doi.org\/10.1093\/jnci\/djx166.","journal-title":"J Natl Cancer Inst"},{"key":"1380_CR35","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.cell.2020.01.026","volume":"180","author":"Y Dou","year":"2020","unstructured":"Dou Y, Kawaler EA, Cui Zhou D, Gritsenko MA, Huang C, Blumenberg L, et al. Proteogenomic Characterization of Endometrial Carcinoma. Cell. 2020;180:729\u2013748.e726.","journal-title":"Cell"},{"issue":"1","key":"1380_CR36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12885-020-6515-2","volume":"20","author":"F Zhou","year":"2020","unstructured":"Zhou F, Wang D, Wei W, Chen H, Shi H, Zhou N, et al. Comprehensive profiling of circular RNA expressions reveals potential diagnostic and prognostic biomarkers in multiple myeloma. BMC Cancer. 2020;20(1):40. https:\/\/doi.org\/10.1186\/s12885-020-6515-2.","journal-title":"BMC Cancer"},{"issue":"1","key":"1380_CR37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13046-019-1071-9","volume":"38","author":"Y Feng","year":"2019","unstructured":"Feng Y, Zhang L, Wu J, Khadka B, Fang Z, Gu J, et al. CircRNA circ_0000190 inhibits the progression of multiple myeloma through modulating miR-767-5p\/MAPK4 pathway. J Exp Clin Cancer Res. 2019;38(1):54. https:\/\/doi.org\/10.1186\/s13046-019-1071-9.","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"1380_CR38","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/leu.2013.383","volume":"28","author":"W Zhou","year":"2014","unstructured":"Zhou W, Yang Y, Gu Z, Wang H, Xia J, Wu X, et al. ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma. Leukemia. 2014;28(5):1155\u20138. https:\/\/doi.org\/10.1038\/leu.2013.383.","journal-title":"Leukemia"},{"issue":"3","key":"1380_CR39","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1158\/1541-7786.MCR-17-0197","volume":"16","author":"RA Denu","year":"2018","unstructured":"Denu RA, Shabbir M, Nihal M, Singh CK, Longley BJ, Burkard ME, et al. Centriole Overduplication is the predominant mechanism leading to centrosome amplification in melanoma. Mol Cancer Res. 2018;16(3):517\u201327. https:\/\/doi.org\/10.1158\/1541-7786.MCR-17-0197.","journal-title":"Mol Cancer Res"},{"issue":"3","key":"1380_CR40","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1091\/mbc.e04-10-0939","volume":"16","author":"G Guarguaglini","year":"2005","unstructured":"Guarguaglini G, Duncan PI, Stierhof YD, Holmstrom T, Duensing S, Nigg EA. The forkhead-associated domain protein Cep170 interacts with polo-like kinase 1 and serves as a marker for mature centrioles. Mol Biol Cell. 2005;16(3):1095\u2013107. https:\/\/doi.org\/10.1091\/mbc.e04-10-0939.","journal-title":"Mol Biol Cell"},{"issue":"1","key":"1380_CR41","doi-asserted-by":"publisher","first-page":"10072","DOI":"10.1038\/ncomms10072","volume":"6","author":"S Pillai","year":"2015","unstructured":"Pillai S, Nguyen J, Johnson J, Haura E, Coppola D, Chellappan S. Tank binding kinase 1 is a centrosome-associated kinase necessary for microtubule dynamics and mitosis. Nat Commun. 2015;6(1):10072. https:\/\/doi.org\/10.1038\/ncomms10072.","journal-title":"Nat Commun"},{"issue":"5","key":"1380_CR42","doi-asserted-by":"publisher","first-page":"e1005243","DOI":"10.1371\/journal.pgen.1005243","volume":"11","author":"M Panic","year":"2015","unstructured":"Panic M, Hata S, Neuner A, Schiebel E. The centrosomal linker and microtubules provide dual levels of spatial coordination of centrosomes. PLoS Genet. 2015;11(5):e1005243. https:\/\/doi.org\/10.1371\/journal.pgen.1005243.","journal-title":"PLoS Genet"},{"issue":"33","key":"1380_CR43","doi-asserted-by":"publisher","first-page":"9304","DOI":"10.1073\/pnas.1608783113","volume":"113","author":"I Cervenka","year":"2016","unstructured":"Cervenka I, Valnohova J, Bernatik O, Harnos J, Radsetoulal M, Sedova K, et al. Dishevelled is a NEK2 kinase substrate controlling dynamics of centrosomal linker proteins. Proc Natl Acad Sci U S A. 2016;113(33):9304\u20139. https:\/\/doi.org\/10.1073\/pnas.1608783113.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1380_CR44","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3389\/fgene.2020.00228","volume":"11","author":"M Beksac","year":"2020","unstructured":"Beksac M, Balli S, Akcora Yildiz D. Drug targeting of genomic instability in multiple myeloma. Front Genet. 2020;11:228. https:\/\/doi.org\/10.3389\/fgene.2020.00228.","journal-title":"Front Genet"},{"issue":"15_suppl","key":"1380_CR45","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1200\/JCO.2019.37.15_suppl.3094","volume":"37","author":"ER Plummer","year":"2019","unstructured":"Plummer ER, Kristeleit RS, Cojocaru E, Haris NM, Carter L, Jones RH, et al. A first-in-human phase I\/II trial of SRA737 (a Chk1 inhibitor) in subjects with advanced cancer. J Clin Oncol. 2019;37(15_suppl):3094. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.3094.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1380_CR46","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1080\/13543784.2019.1694661","volume":"28","author":"P Dent","year":"2019","unstructured":"Dent P. Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancer. Expert Opin Investig Drugs. 2019;28(12):1095\u2013100. https:\/\/doi.org\/10.1080\/13543784.2019.1694661.","journal-title":"Expert Opin Investig Drugs"},{"key":"1380_CR47","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s10637-019-00873-6","volume":"38","author":"JC Bendell","year":"2019","unstructured":"Bendell JC, Bischoff HG, Hwang J, Reinhardt HC, Zander T, Wang X, et al. A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer. Investig New Drugs. 2019;38:1145.","journal-title":"Investig New Drugs"},{"issue":"7","key":"1380_CR48","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/s41388-019-1079-9","volume":"39","author":"NJH Warren","year":"2020","unstructured":"Warren NJH, Eastman A. Comparison of the different mechanisms of cytotoxicity induced by checkpoint kinase I inhibitors when used as single agents or in combination with DNA damage. Oncogene. 2020;39(7):1389\u2013401. https:\/\/doi.org\/10.1038\/s41388-019-1079-9.","journal-title":"Oncogene"}],"updated-by":[{"DOI":"10.1186\/s12943-026-02734-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000}}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-021-01380-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-021-01380-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-021-01380-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T01:49:49Z","timestamp":1784252989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-021-01380-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,5]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1380"],"URL":"https:\/\/doi.org\/10.1186\/s12943-021-01380-0","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,5]]},"assertion":[{"value":"4 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12943-026-02734-2","URL":"https:\/\/doi.org\/10.1186\/s12943-026-02734-2","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were conducted in accordance with the Government-published recommendations for the Care and Use of Laboratory Animals and approved by the Institutional Ethics Review Boards of Nanjing University of Chinese Medicine (Ethics Registration no. 201905A003).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors of this article have directly participated in the planning and drafting and all authors listed have read and approved the final version including details and images.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"84"}}